FENC— FENNEC PHARMACEUTICALS INC.

MaterialsBiotechnology$402M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Product sales, net	$44.6M+50.9%	$29.6M+39.2%	$21.3M	—
Licensing revenue	$18.0M	—	—	—
Total net revenues	$44.6M-6.1%	$47.5M+123.7%	$21.3M+1284.5%	$1.5M
Cost of product sales	$3.8M+18.2%	$3.2M+152.9%	$1.3M	—
Research and development	$250K-18.6%	$307K+448.2%	$56K-98.4%	$3.5M
Selling and marketing	$18.6M+1.0%	$18.4M+52.0%	$12.1M+335.3%	$2.8M
General and administrative	$28.3M+22.7%	$23.1M+12.0%	$20.6M+16.2%	$17.7M
Total operating expenses	$50.9M+13.2%	$45.0M+32.2%	$34.0M+41.5%	$24.0M
(Loss)/income from operations	-$6.3M-344.6%	$2.6M+120.1%	-$12.8M+43.5%	-$22.6M
Other income/(expense)	—	—	—	—
Unrealized foreign exchange gain/(loss)	$28K+134.1%	-$82K-1740.0%	$5K+155.6%	-$9K
Amortization expense	-$64K+28.1%	-$89K+69.0%	-$287K-92.6%	-$149K
Unrealized loss on securities	-$2K+97.5%	-$81K-107.7%	-$39K+78.8%	-$184K
Loss on debt extinguishment	-$2.0M	—	—	—
Interest income	$787K-53.2%	$1.7M+281.4%	$441K+126.2%	$195K
Interest expense	-$2.1M+48.9%	-$4.1M-19.9%	-$3.4M-247.0%	-$978K
Total other expense	-$3.4M-27.1%	-$2.6M+19.4%	-$3.3M-191.0%	-$1.1M
Loss before income tax	-$9.6M-13470.4%	-$71K+99.6%	-$16.0M	—
Income tax	-$106K+71.0%	-$365K	—	—
Net loss	-$9.7M-2134.2%	-$436K+97.3%	-$16.0M+32.3%	-$23.7M
Basic net loss per common share	-$340.00-1600.0%	-$20.00+96.7%	-$600.00+33.3%	-$900.00
Diluted net loss per common share	-$340.00-1600.0%	-$20.00+96.7%	-$600.00+33.3%	-$900.00
Weighted-average number of common shares outstanding basic	28.6M+4.7%	27.3M+2.7%	26.6M+1.1%	26.3M
Weighted-average number of common shares outstanding diluted	28.6M+4.7%	27.3M+2.7%	26.6M+1.1%	26.3M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.